トップページ

 

PFIZER/WARNER-LAMBERT MERGER

Pfizer to acquire Pharmacia

   spin-off of Monsanto

  ファイザーのファルマシア買収 「来年(2003)にずれ込み」

   → Pharmacia Shareholders Vote to Approve Merger with Pfizer

   → EU to End Pfizer-Pharmacia Probe Soon

→ 米国ファイザー社とファルマシア社が統合       

  日本   ファルマシア・筑波工場の機能縮小  日本法人統合

Pfizer to Acquire Esperion Therapeutics to Extend Its Research Commitment in Cardiovascular Disease

Pfizer to Explore Strategic Alternatives for Consumer Healthcare Business

J&Jがファイザーから大衆薬事業買収

米ファイザー、1万人削減 製造拠点半減

Bayer shares gain on talk of Pfizer interest

米ファイザー、消炎鎮痛剤の健康被害訴訟で和解

Pfizer in Talks to Buy Wyeth in $60 Billion Deal

   Pfizer to acquire Wyeth

Pfizer acquisition agreement would give Wyeth seats on Pfizer board, $4.5 billion breakup fee

GlaxoSmithKline and Pfizer to create a new world-leading, specialist HIV company

Pfizer to Pay $2.3 Billion for Fraudulent Marketing


July 15, 2002                  

Pfizer to acquire Pharmacia Corporation for $60 billion in stock, strategically positioning company for long-term leadership in rapidly changing pharmaceutical industry 
  http://www.pfizer.com/are/investors_releases/mn_2002_0715c.cfm


Pfizer Inc and Pharmacia Corporation jointly announced today that they have signed a definitive agreement providing for Pfizer to acquire Pharmacia in a stock-for-stock transaction valued at $60 billion, expanding the company's core strengths in pharmaceuticals and health care.

Pharmacia also announced that its Board of Directors intends to proceed with its previously announced
spin-off of its remaining 84% ownership of Monsanto to its current shareholders.


Pharmacia Newsroom

 http://www.pharmacia.com/newsroom/script_press.asp?id=330  

Frequently asked questions regarding spin-off of Monsanto        spin-off

On November 28, 2002, Pharmacia Corporation's Board of Directors approved the intent to spin-off the remaining 84% of Monsanto in a tax-free dividend to Pharmacia shareholders of record. The spin-off of Monsanto will allow both Pharmacia and Monsanto to devote management time and efforts to the core strategies of each business.


November 12, 2001 Reuters            → spin-off of Monsanto  変遷図

"Pharmacia seen spinning off Monsanto"         
  
http://www.biotech-info.net/Pharmacia_sells_Monsanto.html


Pharmacia Corp. will likely spin off Monsanto Co. to shareholders next spring as the drug company seeks to rid itself of its volatile agricultural business, analysts said.


June 19, 2000

FTC GRANTS FINAL CLEARANCE FOR PFIZER/WARNER-LAMBERT MERGER, TRANSACTION COMPLETED TODAY
New Pfizer Combines Complementary Pharmaceutical Portfolios, Strong Research Platforms and Outstanding Global Sales and Marketing Capabilities
   
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=105&STORY=/www/story/06-19-2000/0001246843

Pfizer Inc said today that the Federal Trade Commission (FTC) has accepted a consent decree clearing the way for the company's merger with Warner-Lambert. The merger was completed today.


2002/12/5 日本経済新聞

ファイザーのファルマシア買収 CE0「来年にずれ込み」

世界最大の製薬会社、米ファイザーのヘンリー・マッキンネル会長兼最高経営責任者(CEO)は日本経済新聞記者と会い、「当初年内の完了を予定していた米ファルマシアの買収が来年にずれ込む可能性が高くなった」と語った。


2002/12/9 Pharmacia

Pharmacia Corporation Shareholders Vote to Approve Merger with Pfizer Inc.
  http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=105&STORY=/www/story/12-09-2002/0001854440


Pharmacia Corporation today announced that its shareholders voted to approve the company
s proposed merger with Pfizer Inc. at a special meeting of shareholders meeting held in Wilmington, Delaware.


2003/2/6    

EU to End Pfizer-Pharmacia Probe Soon
   http://asia.news.yahoo.com/030206/3/r63f.html



2003/4/16 PFIZER

PFIZER AND PHARMACIA COMBINE OPERATIONS, CREATING WORLD'S LARGEST RESEARCH-BASED PHARMACEUTICAL COMPANY
   http://www.pfizer.co.uk/template2.asp?pageid=192

Pfizer Inc and Pharmacia Corporation combined operations today, bringing together two of the world's fastest-growing and most innovative companies. The new Pfizer is the world's leading research-based pharmaceutical company.

Combined Product Portfolio Features 14 Therapeutic Leaders; Sales Force is "Distinct Advantage" for Sustaining Growth

Expanded Global Leadership for Pharmaceuticals, Consumer Products and Animal Health

Pfizer R&D to Apply New Technologies, Focus on Productivity

Substantial Financial Strength, Significant Cost Savings, Increased Operational Flexibility


2003/04/17 ファイザー製薬

米国ファイザー社とファルマシア社が統合
   両社の日本法人は8月1日に統合、「ファイザー株式会社」に
   
 http://www.pfizer.co.jp/pfizer/company/press/2003/2003_04_17_2.html


ファイザー製薬株式会社の親会社ファイザー社(本社:米国ニューヨーク市)とファルマシア株式会社の親会社ファルマシア社(本社:米国ニュージャージー州ピーパック)は、4月14日(米国時間)、米国連邦取引委員会の承認をもって、統合手続きがすべて完了し、4月16日(米国時間)より事業を統合しました。

両本社の統合により、それぞれの日本法人であるファイザー製薬株式会社とファルマシア株式会社は、本年8月1日をもって日本での事業を統合すべく、今後さらに具体的な作業を推し進めることとなります。8月1日の統合にあたっては、社名を「ファイザー株式会社」と改め、また本社を「新宿文化クイントビル」(渋谷区代々木)に移転する予定です。


日本経済新聞 2003/6/12

ファイザー製薬 筑波工場の機能縮小 ファルマシアと統合で

米系製薬大手ファイザー製薬は米ファルマシア日本法人と8月に統合するのに伴い、ファルマシア筑波工場(つくば市)の機能を縮小する。


2003/07/31 ファイザー製薬

8月1日、ファイザー製薬、ファルマシア株式会社と統合
 
 http://www.pfizer.co.jp/pfizer/company/press/2003/2003_07_31.html


ファイザー製薬は、創業50周年を迎える8月1日をもってファルマシアを統合します。

<日本のファイザーグループ各社の概要>

1)ファイザー株式会社
(1)資本金 648億円
(2)従業員数 約6,000名
(3)事業内容 医療用医薬品、一般用医薬品、動物用医薬品、農薬の製造・販売・輸出入
(4)売上 ファイザー製薬(株) 2,488億9,300万円
ファルマシア(株)   1,131億3,000万円 (2002年度)
(5)代表取締役社長 アラン・B・ブーツ
(6)本社 東京都渋谷区代々木3−22−7新宿文化クイントビル
(7)中央研究所 愛知県知多郡
(8)工場 愛知県知多郡、茨城県つくば市
(9)事業所・営業所 73カ所
     
2)カプスゲル・ジャパン株式会社
(1)資本金 3億1,000万円(ファイザー株式会社100%出資)
(2)従業員数 約150名
(3)事業内容 医薬品/健康食品用ハード・カプセル及びカプセル充填機の製造・販売
(4)売上 63億1,000万円(2002年度)
(5)取締役会長 アラン・B・ブーツ、代表取締役社長:大貫 博
(6)本社・工場 神奈川県相模原市南橋本4−3−36
     
3)ファルマシア有限会社
(1)資本金 195億円7,950万円
(2)従業員数 約80名
(3)事業内容 医薬品、動物用医薬品、診断薬、医療機器の製造・輸入・販売
(4)代表取締役会長 アラン・B・ブーツ、代表取締役社長:木村 誠一
(5)本社 東京都新宿区西新宿3−20−2 東京オペラシティタワー

 

<日本におけるファイザー50年の歩み>


December 21, 2003 Pfizer

Pfizer to Acquire Esperion Therapeutics to Extend Its Research Commitment in Cardiovascular Disease
 http://www.pfizer.com/are/investors_releases/mn_2003_1221.cfm

Pfizer Inc today announced it has entered into an agreement to acquire Esperion Therapeutics, Inc., a biopharmaceutical company focused on the development of high density lipoprotein (HDL) targeted therapies for the treatment of cardiovascular disease.


Esperion Therapeutics brings a novel approach to the emerging area of HDL Therapy and reverse lipid transport for the acute treatment of cardiovascular disease. Recently, Esperion published positive Phase II results on a biopharmaceutical compound (ETC-216) that showed a statistically significant reduction in plaque volume in patients with acute coronary syndrome at the end of six weeks. Esperion also has a second biopharmaceutical compound, ETC-588, in Phase II and a number of early-stage compounds.


Esperion Therapeutics, Inc    http://www.esperion.com/

Esperion Therapeutics, Inc., is a biopharmaceutical company dedicated to the discovery, development and commercialization of a novel class of therapies to treat cardiovascular and metabolic diseases, including atherosclerosis, as they relate to high density lipoprotein cholesterol, HDL-C, also known as the goodcholesterol.



Esperion was founded in 1998 by, among others,
members of the Warner-Lambert/Parke-Davis (now Pfizer) team that discovered and developed atorvastatin, the highly successful multibillion-dollar drug. Since that time, an additional group of exceptional scientists and specialists has joined the Company. Many of these individuals have been instrumental in the discovery, development and commercialization of several of the pharmaceutical industrys most successful therapies. It is this combined team that makes Esperion a leading enterprise in HDL drug discovery and research.


2006/2/7 Pfizer

Pfizer to Explore Strategic Alternatives for Consumer Healthcare Business
http://www.pfizer.com/pfizer/are/news_releases/2006pr/mn_2006_0207.jsp

In response to media inquiries ahead of the company's February 10 meeting with financial analysts, Pfizer Inc said today it will be exploring strategic alternatives for Pfizer Consumer Healthcare (PCH). These alternatives include retaining, spinning off or selling the business.


2007/1/23 日本経済新聞夕刊

米ファイザー、
1万人削減 来年末メド
 製造拠点半減 愛知の研究所閉鎖

 製薬世界最大手の米ファイザーは22日、2008年末までに全世界の従業員の1割にあたる1万人を削減すると発表した。製造拠点を03年時点の半分に相当する48カ所に絞り込むほか、日本では名古屋工場にある中央研究所
(愛知県武豊町)を閉鎖する。主力薬品が相次いで特許切れを迎えるのに備え、経費削減を拡大する。
 
昨年11月に米国の販売部門の2千人強を削減するとしたリストラ計画を拡大する。

 


日本経済新聞 2007/9/21

閉鎖予定のファイザー研究所 従業員が買収し新会社
 愛知の中央研 国内外ファンドも出資

 製薬世界最大手、米ファイザーの中央研究所(愛知県武豊町)が来年4月にも研究者らの出資による新薬開発のベンチャー企業として独立する。米本社が閉鎖を決めたことから、約80人の研究者が中心となって新会社を設立し、研究施設や新薬候補物質などの資産を譲り受ける。国内外の投資ファンドからも資金調達する考え。日本では例が少ない従業員による企業買収(EBO)によって再出発する。
 

 国内のEBOの事例としては、2000年に旭電化工業(現ADEKA)が4工場を従業員に売却。最近では明光商会やポッカコーポレーションなど、経営陣と従業員による企業買収(MEDO)が増えている。


2008/7/1 日本経済新聞夕刊

ファイザーの研究所員ら ラクオリア創薬 月内に設立・独立

 製薬業界最大手の米ファイザーが閉鎖を決めた中央研究所(愛知県武豊町)の従業員らが7月に新会社「ラクオリア創薬」を設立し独立する。資金.を確保するため投資会社を探していたが、ベンチャーキャピタルのエヌ・アイ・エフSMBCベンチャーズなどが新会社に出資することを決めた。
 業績不振からファイザーが昨年に同研究所の閉鎖を決定したことから、.同研究所の長久厚所長が中心となり、新会社設立を目指していた。当初、今春に独立する計画だったが、世界的な株安などを背景に投資家集めが難航していた。


2008/07/03 ファイザー

旧ファイザー中央研究所、ファイザー社より独立
ラクオリア創薬株式会社としてスタート

 米国ファイザー社の研究開発グループの一翼を担ってきた愛知県の中央研究所はこのたび、日欧の投資会社の出資とファイザー社の支援により、独立した新たな研究開発型ベンチャー企業であるラクオリア創薬株式会社(RaQualia Pharma Inc.)として7月1日に事業を開始いたしましたのでご報告いたします。

 新会社は、自ら新薬の化合物を開発する創薬ベンチャー企業であり、世界において最も革新的な新薬を生み出すグローバル研究開発型ライフサイエンス企業を目指します。ラクオリア創薬株式会社の従業員は70人です。本社は、旧ファイザー(株)中央研究所が所在した愛知県知多郡武豊町に置き、既存の研究施設や最先端研究機器を活用いたします。

 
【会社概要】

 社 名:ラクオリア創薬株式会社(RaQualia Pharma Inc.)
 代表取締役社長&CEO:長久 厚(ながひさ あつし)
 本 社:愛知県知多郡武豊町字5号地2番地
 従業員:70名(2008年7月1日現在)
 事業内容:医薬品の研究開発、医薬品及び臨床開発候補品に関わる基盤技術の知的財産の販売及び使用許諾
 資本金:1000万円(2008年7月1日現在)
 主な出資予定者:(1)エヌ・アイ・エフSMBCベンチャーズ株式会社
            (2)コラーキャピタル(
Coller Capital)(英国)
            (3)ファイザー株式会社

エヌ・アイ・エフSMBCベンチャーズ:
 2005年10月に大和証券グループのエヌ・アイ・エフ ベンチャーズと三井住友フィナンシャルグループのSMBCキャピタルが合併

コラーキャピタル (Coller Capital):
1990 年に設立されたプライベートエクイティの投資会社。本社英国ロンドン。欧米、アジアの約 200 の機関投資家を顧客とし、約 8,000 億円の資産の投資アドバイスを行う。2007年 4 月に募集したコラーインターナショナルパートナーズ 5 号は、約 4,800 億円 のコミットメントを有す。投資対象は全世界のプライベートエクイティファンド(VC ファンド、バイアウトファンド等)と未上場株式。


日本経済新聞 2008/7/4

ファイザー中央研研究者 111億円集め新会社 新薬候補の開発を継承


 投資会社9社が合計89億円を出資。うち38億円を負担するエヌ・アイ・エフが32%の株式を持つ筆頭株主となる。ファイザーも22億円を出資し、19%の株式を保有する第三位株主として協力していく。

 胃や腸の治療薬や鎮痛剤を研究開発し、「毎年2つの新薬候補品を生み出し、2010年12月期に売上高41億円を目指す」(長久社長)。10年後半から11年前半をメドに株式公開を目指す。


2006/11/28

As Initial Step in Transformation Strategy and Review of All Business Units, Pfizer to Align U.S. Sales Organization to Support Its Key Products and Customer Needs
Pfizer Says Representatives Are Critical Competitive Advantage and Core Asset in Communicating Value of Medicines

As part of its strategy to most effectively and efficiently meet customer needs as well as match the organization's business needs, Pfizer said today that it will realign its U.S. sales organization.

The company will reduce the U.S. sales organization by approximately 20 percent, while maintaining strong support for all of its in-line products, including Lipitor, Celebrex and Geodon, as well as important new products such as Lyrica, Exubera, Chantix and Sutent.

Pfizer announced in mid-October that it would undertake a comprehensive review of every aspect of its company-wide operations with the goals of being more agile, effective and capable of best ensuring success today and in the future. In January, Pfizer will present its long-term outlook and its additional actions for transforming the company.


2009/1/23 Bloomberg

Pfizer in Talks to Buy Wyeth in $60 Billion Deal

Pfizer Inc., seeking to replace revenue it will lose within three years to generic competition, is in talks to buy Wyeth, according to three people familiar with the discussions. Wyeth shares jumped the most in a decade.

A deal may be worth more than $60 billion, based on a 20 percent premium over Wyeth's share price yesterday. Pfizer, the world's biggest drugmaker, has been negotiating with Madison, New Jersey-based Wyeth for months, one person said. A combination would help Pfizer offset some of the $12 billion in sales it will start losing in 2011 when its top-selling Lipitor cholesterol pill gets generic competition.

With $25.5 billion in cash and short-term assets as of Sept. 30, New York-based Pfizer is one of the world's most cash-rich companies. It would gain Wyeth's Prevnar vaccine, recommended by the U.S. government as a childhood shot against pneumonia, and dependable sales not threatened by generics. The combined company would have annual sales of more than $70 billion, 55 percent more than the world's second-biggest drugmaker, GlaxoSmithKline Plc.


2009/1/26 Pfizer 

PFIZER TO ACQUIRE WYETH, CREATING THE WORLD'S PREMIER BIOPHARMACEUTICAL COMPANY
 Diversification, Flexibility and Scale Position New Company for Success in Dynamic Global Health Care Environment

 Establishes Leadership in Human, Animal, and Consumer Health, including Primary and Specialty Care; in Vaccines, Biologics and Small Molecules; and Across Developed and Emerging Markets

 Unique and Flexible Business Model Features Focus and Agility of Smaller Enterprises Backed by Resources and Scale of Global Company

 Combination Strengthens Platform for Improved, Consistent, and Stable Earnings Growth and Sustainable Shareholder Value

 New Company Will Promote Health and Wellness and Respond More Effectively to Unmet Needs of Patients, Physicians, and Customers Around the World

Pfizer and Wyeth today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at $50.19 per share, or a total of approximately $68 billion. The Boards of Directors of both companies have approved the combination.

Financial Highlights
Under the terms of the transaction, each outstanding share of Wyeth common stock will be converted into the right to receive
$33 in cash and 0.985 of a share of Pfizer common stock, subject to the terms of the merger agreement. Based on the closing price of Pfizer stock as of January 23, 2009, the stock component is valued at $17.19 per share. The transaction provides immediate value to Wyeth shareholders through the cash component, as well as continued participation in the future prospects expected to result from the combination through their ownership of approximately 16 percent of Pfizer's shares.


September 2, 2009 Justice Department

Justice Department Announces Largest Health Care Fraud Settlement in Its History

Pfizer to Pay $2.3 Billion for Fraudulent Marketing

American pharmaceutical giant Pfizer Inc. and its subsidiary Pharmacia & Upjohn Company Inc. (hereinafter together "Pfizer") have agreed to pay $2.3 billion, the largest health care fraud settlement in the history of the Department of Justice, to resolve criminal and civil liability arising from the illegal promotion of certain pharmaceutical products, the Justice Department announced today.

Pharmacia & Upjohn Company has agreed to plead guilty to a felony violation of the Food, Drug and Cosmetic Act for misbranding Bextra with the intent to defraud or mislead. Bextra is an anti-inflammatory drug that Pfizer pulled from the market in 2005. Under the provisions of the Food, Drug and Cosmetic Act, a company must specify the intended uses of a product in its new drug application to FDA. Once approved, the drug may not be marketed or promoted for so-called "off-label" uses ? i.e., any use not specified in an application and approved by FDA. Pfizer promoted the sale of Bextra for several uses and dosages that the FDA specifically declined to approve due to safety concerns. The company will pay a criminal fine of $1.195 billion, the largest criminal fine ever imposed in the United States for any matter. Pharmacia & Upjohn will also forfeit $105 million, for a total criminal resolution of $1.3 billion.

In addition, Pfizer has agreed to pay $1 billion to resolve allegations under the civil False Claims Act that the company illegally promoted four drugs - Bextra; Geodon, an anti-psychotic drug; Zyvox, an antibiotic; and Lyrica, an anti-epileptic drug - and caused false claims to be submitted to government health care programs for uses that were not medically accepted indications and therefore not covered by those programs. The civil settlement also resolves allegations that Pfizer paid kickbacks to health care providers to induce them to prescribe these, as well as other, drugs. The federal share of the civil settlement is $668,514,830 and the state Medicaid share of the civil settlement is $331,485,170. This is the largest civil fraud settlement in history against a pharmaceutical company.

As part of the settlement, Pfizer also has agreed to enter into an expansive corporate integrity agreement with the Office of Inspector General of the Department of Health and Human Services. That agreement provides for procedures and reviews to be put in place to avoid and promptly detect conduct similar to that which gave rise to this matter.

Whistleblower lawsuits filed under the qui tam provisions of the False Claims Act that are pending in the District of Massachusetts, the Eastern District of Pennsylvania and the Eastern District of Kentucky triggered this investigation. As a part of todays resolution, six whistleblowers will receive payments totaling more than $102 million from the federal share of the civil recovery.

The U.S. Attorneys offices for the District of Massachusetts, the Eastern District of Pennsylvania, and the Eastern District of Kentucky, and the Civil Division of the Department of Justice handled these cases. The U.S. Attorneys Office for the District of Massachusetts led the criminal investigation of Bextra. The investigation was conducted by the Office of Inspector General for the Department of Health and Human Services (HHS), the FBI, the Defense Criminal Investigative Service (DCIS), the Office of Criminal Investigations for the Food and Drug Administration (FDA), the VeteransAdministrations (VA) Office of Criminal Investigations, the Office of the Inspector General for the Office of Personnel Management (OPM), the Office of the Inspector General for the United States Postal Service (USPS), the National Association of Medicaid Fraud Control Units and the offices of various state Attorneys General.

"Todays landmark settlement is an example of the Department of Justices ongoing and intensive efforts to protect the American public and recover funds for the federal treasury and the public from those who seek to earn a profit through fraud. It shows one of the many ways in which federal government, in partnership with its state and local allies, can help the American people at a time when budgets are tight and health care costs are increasing," said Associate Attorney General Tom Perrelli. "This settlement is a testament to the type of broad, coordinated effort among federal agencies and with our state and local partners that is at the core of the Department of Justices approach to law enforcement."

"This historic settlement will return nearly $1 billion to Medicare, Medicaid, and other government insurance programs, securing their future for the Americans who depend on these programs," said Kathleen Sebelius, Secretary of Department of Health and Human Services. "The Department of Health and Human Services will continue to seek opportunities to work with its government partners to prosecute fraud wherever we can find it. But we will also look for new ways to prevent fraud before it happens. Health care is too important to let a single dollar go to waste."

"Illegal conduct and fraud by pharmaceutical companies puts the public health at risk, corrupts medical decisions by health care providers, and costs the government billions of dollars," said Tony West, Assistant Attorney General for the Civil Division. "This civil settlement and plea agreement by Pfizer represent yet another example of what penalties will be faced when a pharmaceutical company puts profits ahead of patient welfare."

"The size and seriousness of this resolution, including the huge criminal fine of $1.3 billion, reflect the seriousness and scope of Pfizers crimes," said Mike Loucks, acting U.S. Attorney for the District of Massachusetts. "Pfizer violated the law over an extensive time period. Furthermore, at the very same time Pfizer was in our office negotiating and resolving the allegations of criminal conduct by its then newly acquired subsidiary, Warner-Lambert, Pfizer was itself in its other operations violating those very same laws. Todays enormous fine demonstrates that such blatant and continued disregard of the law will not be tolerated."

"Although these types of investigations are often long and complicated and require many resources to achieve positive results, the FBI will not be deterred from continuing to ensure that pharmaceutical companies conduct business in a lawful manner," said Kevin Perkins, FBI Assistant Director, Criminal Investigative Division.

"This resolution protects the FDA in its vital mission of ensuring that drugs are safe and effective. When manufacturers undermine the FDAs rules, they interfere with a doctors judgment and can put patient health at risk," commented Michael L. Levy, U.S. Attorney for the Eastern District of Pennsylvania. "The public trusts companies to market their drugs for uses that FDA has approved, and trusts that doctors are using independent judgment. Federal health dollars should only be spent on treatment decisions untainted by misinformation from manufacturers concerned with the bottom line."

"This settlement demonstrates the ongoing efforts to pursue violations of the False Claims Act and recover taxpayer dollars for the Medicare and Medicaid programs," noted Jim Zerhusen, U.S. Attorney for the Eastern District of Kentucky.

"This historic settlement emphasizes the governments commitment to corporate and individual accountability and to transparency throughout the pharmaceutical industry," said Daniel R. Levinson, Inspector General of the United States Department of Health and Human Services. "The corporate integrity agreement requires senior Pfizer executives and board members to complete annual compliance certifications and opens Pfizer to more public scrutiny by requiring it to make detailed disclosures on its Web site. We expect this agreement to increase integrity in the marketing of pharmaceuticals."

"The off-label promotion of pharmaceutical drugs by Pfizer significantly impacted the integrity of TRICARE, the Department of Defenses healthcare system," said Sharon Woods, Director, Defense Criminal Investigative Service. "This illegal activity increases patientscosts, threatens their safety and negatively affects the delivery of healthcare services to the over nine million military members, retirees and their families who rely on this system. Todays charges and settlement demonstrate the ongoing commitment of the Defense Criminal Investigative Service and its law enforcement partners to investigate and prosecute those that abuse the governments healthcare programs at the expense of the taxpayers and patients."

"Federal employees deserve health care providers and suppliers, including drug manufacturers, that meet the highest standards of ethical and professional behavior," said Patrick E. McFarland, Inspector General of the U.S. Office of Personnel Management. "Todays settlement reminds the pharmaceutical industry that it must observe those standards and reflects the commitment of federal law enforcement organizations to pursue improper and illegal conduct that places health care consumers at risk."

"Health care fraud has a significant financial impact on the Postal Service. This case alone impacted more than 10,000 postal employees on workerscompensation who were treated with these drugs," said Joseph Finn, Special Agent in Charge for the Postal Services Office of Inspector General. "Last year the Postal Service paid more than $1 billion in workerscompensation benefits to postal employees injured on the job."


2014/4/29 

Pfizer、AstraZenecaに買収提案

米ファイザーは28日、今年1月に588億ポンド(989億ドル)でアストラゼネカを買収するため、同社に1月に接触したことを明らかにした。また、ファイザーは、4月26日にも買収に向けた協議をするため、アストラゼネカに接触したことを明らかにした。

米医薬品大手ファイザーのイアン・リード最高経営責任者(CEO)は28日、同業の英アストラゼネカに対する約1000億ドルの買収提案をめぐり、英政府に連絡を取ったことを明らかにした。

リードCEOは記者団との電話会議で、アストラゼネカ買収をめぐり、「英政府に今朝連絡を取り、初期段階の協議を行った」ことを明らかにした。

そのうえで、買収が実現すれば「世界最大の医薬品企業が誕生し、約1000億ドルの資金が英経済に注入される」と語った。

買収案をめぐっては、英医薬品セクターの雇用が脅かされるとして懸念が広がっている。

リードCEOは、英政府による最近の税控除措置を踏まえ、英国が薬学研究や医薬品製造で魅力的な国としつつも、将来の投資や雇用に関して確約することはできないと述べた。
 

アストラゼネカは28日、ファイザーから同社買収に向けた協議の提案を拒否したことを明らかにした。

アストラゼネカは「この話し合いでファイザーの会長はアストラゼネカ買収のための具体的な提案は行わなかった」とし、ファイザーからの協議の要請を検討したが、具体的で魅力的な提案がないため、協議は適切でないと判断した、と発表した。


May 16, 2016 

Pfizer to Acquire Anacor

  • Strong fit with Pfizer’s Inflammation and Immunology portfolio
  • Expected to enhance near-term revenue growth for the innovative business
  • Anacor’s flagship asset, crisaborole, has a New Drug Application under review by the U.S. Food and Drug Administration (FDA), is a differentiated non-steroidal topical PDE4 inhibitor with compelling clinical data, and if approved, has the potential to be an important first-line treatment option for patients with atopic dermatitis
Pfizer Inc. and Anacor Pharmaceuticals, Inc.  today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Anacor for $99.25 per Anacor share, in cash, for a total transaction value, net of cash, of approximately $5.2 billion, which assumes the conversion of Anacor’s outstanding convertible notes. The Boards of Directors of both companies have unanimously approved the transaction. Anacor’s flagship asset, crisaborole, a differentiated non-steroidal topical PDE4 inhibitor with anti-inflammatory properties, is currently under review by the U.S. FDA for the treatment of mild-to-moderate atopic dermatitis, commonly referred to as eczema.
             
アトピー性皮膚炎に有効な新たな非ステロイド系薬

“We believe the acquisition of Anacor represents an attractive opportunity to address a significant unmet medical need for a large patient population with mild-to-moderate atopic dermatitis, which currently has few safe topical treatments available,” said Albert Bourla, Group President of Pfizer’s Global Innovative Pharma and Global Vaccines, Oncology and Consumer Healthcare Businesses. “Crisaborole is a differentiated asset with compelling clinical data that, if approved, has the potential to be an important first-line treatment option for these patients and the physicians who treat them.”

“Anacor will be a strong fit with Pfizer’s innovative business, further supporting our strategic focus on Inflammation and Immunology, and is expected to enhance near-term revenue growth for the innovative business. Our dedicated Inflammation and Immunology group has strong existing in-market franchises with Enbrel and Xeljanz, as well as a robust mid-stage pipeline, and this acquisition has the potential to add a near-term U.S. product launch. We believe we are well positioned to maximize crisaborole’s commercial potential through our strong relationships with pediatricians and primary care physicians,” continued Bourla.

In both of its Phase 3 pivotal studies, crisaborole achieved statistically significant results on all primary and secondary endpoints and in March 2016, the FDA accepted for review Anacor’s New Drug Application seeking approval of crisaborole for the potential treatment of mild-to-moderate atopic dermatitis in children and adults. The Prescription Drug User Fee Act (PDUFA) goal date for the completion of the FDA’s review is January 7, 2017. If approved, Pfizer believes peak year sales for crisaborole have the potential to reach or exceed $2.0 billion.

“Today marks the beginning of an exciting new chapter for Anacor, which we believe will deliver significant value to our shareholders,” said Paul L. Berns, Anacor’s Chairman and Chief Executive Officer. “We have a deep respect for Pfizer, and it is clear that they share our commitment to addressing the significant unmet medical needs in inflammatory disease. We are proud of the innovative company that our team has built and are confident that Pfizer will help accelerate Anacor’s important mission given the strength of its global platform and resources.”

Atopic dermatitis is a common, relapsing, chronic, inflammatory skin disorder, with patients displaying a chronic rash characterized by inflammation and itching, often occurring in folds of the skin with symptoms lasting up to 14 days or more. Approximately 18 to 25 million people in the United States suffer from this condition, including between 8 and 18% of infants and children. Atopic dermatitis has been considerably underdiagnosed due to the lack of approved effective systemic agents, and limitations of current topical agents. There have been no new molecular entities for atopic dermatitis in the last 15 years.

Anacor also holds the rights to Kerydin, a topical treatment for onychomycosis (toenail fungus) that is distributed and commercialized by Sandoz Inc. in the U.S.

Pfizer anticipates financing the transaction through existing cash. Pfizer does not expect the transaction to impact its current 2016 financial guidance. Pfizer expects the transaction to be slightly dilutive to Adjusted Diluted Earnings Per Share (EPS)(1) in 2017 with accretion to Adjusted Diluted EPS(1) beginning in 2018 and increasing thereafter.

Under the terms of the merger agreement, a subsidiary of Pfizer will commence a cash tender offer to purchase all of the outstanding shares of Anacor common stock for $99.25 per share in cash. The closing of the tender offer is subject to customary closing conditions, including U.S. antitrust clearance and the tender of a majority of the outstanding shares of Anacor common stock. The merger agreement contemplates that Pfizer will acquire any shares of Anacor that are not tendered into the offer through a second-step merger, which will be completed promptly following the closing of the tender offer. Pfizer expects to complete the acquisition in the third-quarter 2016.

Pfizer’s financial advisors for the transaction were Centerview Partners and Guggenheim Securities, and Wachtell, Lipton, Rosen & Katz acted as its legal advisor. Citi served as Anacor’s financial advisor, and Davis Polk & Wardwell, LLP served as its legal advisor.